Annual Current Liabilities
$290.20 M
-$397.76 M-57.82%
31 December 2023
Summary:
Supernus Pharmaceuticals annual total current liabilities is currently $290.20 million, with the most recent change of -$397.76 million (-57.82%) on 31 December 2023. During the last 3 years, it has risen by +$45.09 million (+18.40%). SUPN annual current liabilities is now -57.82% below its all-time high of $687.96 million, reached on 31 December 2022.SUPN Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$291.51 M
-$17.15 M-5.56%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly total current liabilities is currently $291.51 million, with the most recent change of -$17.15 million (-5.56%) on 30 September 2024. Over the past year, it has increased by +$3.97 million (+1.38%). SUPN quarterly current liabilities is now -60.37% below its all-time high of $735.54 million, reached on 30 June 2022.SUPN Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -57.8% | +1.4% |
| 3 y3 years | +18.4% | +24.2% |
| 5 y5 years | +79.8% | +94.7% |
SUPN Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -57.8% | +18.4% | -60.4% | +24.2% |
| 5 y | 5 years | -57.8% | +80.7% | -60.4% | +94.7% |
| alltime | all time | -57.8% | +3407.3% | -60.4% | +2805.5% |
Supernus Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $291.51 M(-5.6%) |
| June 2024 | - | $308.66 M(-1.9%) |
| Mar 2024 | - | $314.55 M(+8.4%) |
| Dec 2023 | $290.20 M(-57.8%) | $290.20 M(+0.9%) |
| Sept 2023 | - | $287.53 M(+13.8%) |
| June 2023 | - | $252.59 M(-65.5%) |
| Mar 2023 | - | $731.54 M(+6.3%) |
| Dec 2022 | $687.96 M(+118.1%) | $687.96 M(-5.2%) |
| Sept 2022 | - | $725.99 M(-1.3%) |
| June 2022 | - | $735.54 M(+158.5%) |
| Mar 2022 | - | $284.56 M(-9.8%) |
| Dec 2021 | $315.38 M(+28.7%) | $315.38 M(+34.4%) |
| Sept 2021 | - | $234.71 M(-17.2%) |
| June 2021 | - | $283.45 M(+17.7%) |
| Mar 2021 | - | $240.81 M(-1.8%) |
| Dec 2020 | $245.11 M(+52.6%) | $245.11 M(-18.2%) |
| Sept 2020 | - | $299.61 M(+11.3%) |
| June 2020 | - | $269.28 M(+60.0%) |
| Mar 2020 | - | $168.34 M(+4.8%) |
| Dec 2019 | $160.59 M(-0.5%) | $160.59 M(+7.3%) |
| Sept 2019 | - | $149.72 M(+4.0%) |
| June 2019 | - | $143.97 M(-5.1%) |
| Mar 2019 | - | $151.71 M(-6.0%) |
| Dec 2018 | $161.35 M(+31.2%) | $161.35 M(+16.6%) |
| Sept 2018 | - | $138.35 M(+33.1%) |
| June 2018 | - | $103.93 M(-12.7%) |
| Mar 2018 | - | $119.09 M(-3.2%) |
| Dec 2017 | $123.00 M | $123.00 M(+17.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2017 | - | $104.96 M(+22.7%) |
| June 2017 | - | $85.52 M(+4.3%) |
| Mar 2017 | - | $82.00 M(+1.6%) |
| Dec 2016 | $80.74 M(+41.8%) | $80.74 M(+12.7%) |
| Sept 2016 | - | $71.65 M(+9.3%) |
| June 2016 | - | $65.57 M(+21.2%) |
| Mar 2016 | - | $54.12 M(-4.9%) |
| Dec 2015 | $56.93 M(+102.4%) | $56.93 M(+32.0%) |
| Sept 2015 | - | $43.13 M(+18.4%) |
| June 2015 | - | $36.41 M(+35.6%) |
| Mar 2015 | - | $26.86 M(-4.5%) |
| Dec 2014 | $28.12 M(+6.5%) | $28.12 M(+27.1%) |
| Sept 2014 | - | $22.13 M(+15.3%) |
| June 2014 | - | $19.19 M(-29.2%) |
| Mar 2014 | - | $27.10 M(+2.7%) |
| Dec 2013 | $26.40 M(+14.9%) | $26.40 M(+5.3%) |
| Sept 2013 | - | $25.07 M(+56.5%) |
| June 2013 | - | $16.02 M(-40.7%) |
| Mar 2013 | - | $27.01 M(+17.5%) |
| Dec 2012 | $22.98 M(+22.4%) | $22.98 M(-6.5%) |
| Sept 2012 | - | $24.59 M(+12.4%) |
| June 2012 | - | $21.88 M(+9.9%) |
| Mar 2012 | - | $19.91 M(+6.1%) |
| Dec 2011 | $18.77 M(+23.4%) | $18.77 M(+13.7%) |
| Sept 2011 | - | $16.51 M(+8.6%) |
| Dec 2010 | $15.21 M(+51.6%) | $15.21 M(-12.6%) |
| Sept 2010 | - | $17.41 M(+73.5%) |
| Dec 2009 | $10.03 M(+21.3%) | $10.03 M |
| Dec 2008 | $8.27 M | - |
FAQ
- What is Supernus Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual current liabilities year-on-year change?
- What is Supernus Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly current liabilities year-on-year change?
What is Supernus Pharmaceuticals annual total current liabilities?
The current annual current liabilities of SUPN is $290.20 M
What is the all time high annual current liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual total current liabilities is $687.96 M
What is Supernus Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, SUPN annual total current liabilities has changed by -$397.76 M (-57.82%)
What is Supernus Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of SUPN is $291.51 M
What is the all time high quarterly current liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly total current liabilities is $735.54 M
What is Supernus Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, SUPN quarterly total current liabilities has changed by +$3.97 M (+1.38%)